Real-World Efficacy of Second-Line Toripalimab in Patients With Advanced None Small-Cell Lung Cancer
To clarify the real-world efficacy and safety of second-line Toripalimab, we assessed 95 consecutive patients
with advanced nonesmall-cell lung cancer in a retrospective multi center trial.
Non adenocarcinoma and a large number of metastatic sites correlated with poor progression-free sur vival (PFS). PFS and overall survival (OS) were longer in patients with embolization-related adverse events;
however, PFS and OS were shorter in patients with interstitial lung disease